|
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
|
Jan 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms.
|
Jan 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q-New prognostic markers are needed
|
Dec 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.
|
Jun 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Question prompt list responds to information needs of myelodysplastic syndromes patients and caregivers
|
Jun 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiative
|
Jan 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years
|
Jan 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.
|
Mar 2012
|
Leuk Res
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence
|
Aug 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
microRNAs in myelodysplastic syndromes: How much do we know and not know?
|
Mar 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
